Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study To Evaluate The Efficacy Of Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy To Reduce Provoked Allergic Rhinitis Symptoms Using The Nasal Allergen Challenge Model

Trial Profile

A Study To Evaluate The Efficacy Of Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy To Reduce Provoked Allergic Rhinitis Symptoms Using The Nasal Allergen Challenge Model

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Grass pollen hypersensitivity; Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 05 Oct 2018 Planned End Date changed from 4 Jun 2019 to 24 May 2019.
    • 05 Oct 2018 Planned primary completion date changed from 2 Apr 2019 to 25 Mar 2019.
    • 05 Jun 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top